With a strategic emphasis on oncology, we have identified seven drug candidates and developed a robust pipeline of product candidates through collaborations and internal discoveries, including small molecules, monoclonal/bifunctional antibodies and oncolytic virus.

Currently, we have three programs that are being investigated in clinical trials: With fast track designation from FDA, AN2025(buparlisib) is expected to be the first-in-class drug for treating recurrent or static HNSCC (Phase III multi-center clinical trial). AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. AN4005, our clinically most advanced drug candidate from in-house discovery, is a potential first-in-class, orally available, small-molecule PD-L1 inhibitor.

We continue actively advancing four in-house preclinical programs considered to have high global commercial viability, including AN3025, an immune-stimulatory anti-human TNFR2 antibody; AN1025, an oral small molecule of β-catenin degrader; AN8025, a multifunctional antibody as T cell and APC modulator, and AN6025, an oral small molecule HPK1 inhibitor. 

We are working on discovering combination solutions while developing unique cocktail therapy, aiming to bring effective treatment for patients.